Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of “Moderate Buy” from Analysts

Edwards Lifesciences Corporation (NYSE:EW) has received a consensus recommendation of “Moderate Buy” from the twenty-eight research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, fourteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $91.3913.

EW has been the topic of a number of research reports. Oppenheimer cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Stifel Nicolaus increased their price target on Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Canaccord Genuity Group reiterated a “hold” rating and set a $84.00 price target (up from $81.00) on shares of Edwards Lifesciences in a research report on Monday. Finally, JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $84.13 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences has a one year low of $64.89 and a one year high of $87.09. The company’s 50-day simple moving average is $77.68 and its 200-day simple moving average is $77.14. The stock has a market capitalization of $49.39 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 3.97 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the company posted $0.67 earnings per share. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in Edwards Lifesciences during the first quarter worth approximately $26,000. SouthState Corp bought a new stake in Edwards Lifesciences during the first quarter worth approximately $27,000. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences during the second quarter worth approximately $28,000. True Wealth Design LLC increased its holdings in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares in the last quarter. Finally, Costello Asset Management INC bought a new position in shares of Edwards Lifesciences in the first quarter valued at $29,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.